

## FORM 7

### **MONTHLY PROGRESS REPORT FOR SEPTEMBER 2015**

Name of CNSX Issuer: **PACIFIC THERAPEUTICS LTD.** (the "Issuer").

Trading Symbol: **PT**

Number of Outstanding Listed Securities: **41,976,825**

Date: **October 5, 2015**

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**Presently, the Issuer does not have any cash flow from operations.**

2. Provide a general overview and discussion of the activities of management.

**During September, 2015 Management announced that further to the Company's announcement of July 24, 2015 it has closed on its transaction with Forge Therapeutics Inc. of Wyoming ("Forge") to sell the Company's technology assets. This transaction is consistent with the Company's strategy of adding value to drugs by conducting further research and other development activities and then out licensing the therapeutics candidate to a partner for further development and commercialization.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**The Issuer did not produce or acquire, develop, or offer any new products, technologies or services for offer during the month of September.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**The Issuer did not discontinue any services or products other than as noted in 2 above.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**The Issuer did not enter into any new business relationships During September, 2015.**

Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**During September, 2015, there were no expiries or termination of any contracts or agreements between the issuer, its affiliates or third parties or cancellation of any financing arrangements that have been previously announced.**

6. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**As noted in 2 above, during September, 2015 Management announced it has closed on its transaction with Forge Therapeutics Inc. of Wyoming to sell the Company's technology assets.**

**Under the terms of the Agreement, in return for the assets Forge is to issue to the Company 15,000,000 common shares of Forge, and; in the event of a sale to a third party of the assets purchased by Forge under the Agreement, the Company will receive 6% of the value of that transaction, subject to certain conditions. Subject to certain conditions, between the closing of the asset sale to Forge and the issuance of the 15,000,000 common shares, Forge will pay to the Company an annual maintenance fee of \$50,000. Forge will also assume or otherwise cause to be extinguished up to \$500,000 of debt owed to officers and directors of the Company clearing these liabilities from the Company's balance sheet. Subject to the terms of the Agreement, if the 15,000,000 shares are not issued to the Company within 3 years, then the Company may trigger the issuance of the shares, and if at the end of 5 years the shares have not been issued then Forge must return the assets to the Company.**

**This was an arm's length transaction and the consideration was negotiated at arm's length between the parties.**

7. Describe the acquisition of new customers or loss of customers.

**This item is not applicable as the Issuer has no customers or products for sale.**

8. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**As noted in 2 above, during September, 2015 Management announced it has closed on its transaction with Forge Therapeutics Inc. of Wyoming to sell the Company's technology assets.**

9. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

**This item is not applicable to the Issuer.**

Report on any labour disputes and resolutions of those disputes if applicable.

**This item is not applicable to the Issuer.**

10. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**This item is not applicable to the Issuer.**

11. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**Under the terms of the Forge agreement as noted in 2 above, Forge assumed and caused to be extinguished \$500,000 of debt owed to officers and directors of the Company clearing these liabilities from the Company's balance sheet.**

**The Issuer did not incur or repay any debt during September, 2015 other than shareholder loans and the interest of 1% per month on an outstanding Convertible note. The Note may be converted into common shares at price of per share of \$0.05.**

12. Provide details of any securities issued and options or warrants granted.

**N/A**

13. Provide details of any loans to or by Related Persons.

**The Issuer did not loan any funds to Related Persons in September, 2015.**

14. Provide details of any changes in directors, officers or committee members.

**There were no changes to directors, officers or committee members during September, 2015.**

15. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**The trends and risks which are likely to impact the Issuer are detailed in Item 17 of the Issuer's Annual Listing Statement "Risk Factors".**

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated **October 5, 2015**

**Derick Sinclair**

Name of Director or Senior  
Officer

/s/ "Derick Sinclair"

Signature – CFO- PRESIDENT

<b>CEO &amp; President, CFO</b> Official Capacity/Issuer Details Name of Issuer <b>PACIFIC THERAPEUTICS LTD.</b>	For Month End <b>September, 2015</b>	Date of Report YY/MM/D <b>15/10/05</b>
Issuer Address <b>1500 – 409 GRANVILLE STREET</b>		
City/Province/Postal Code <b>VANCOUVER, BC, V6C 1T2</b>	Issuer Fax No.	Issuer Telephone No. <b>(604 ) 924-8000</b>
Contact Name <b>Derick Sinclair</b>	Contact Position <b>CEO &amp; President</b>	Contact Telephone No. <b>(604) 924-8000</b>
Contact Email Address <b>info@PACIFICTHERAPEUTICS.COM</b>	Web Site Address <b><a href="http://WWW.PACIFICTHERAPEUTICS.COM">WWW.PACIFICTHERAPEUTICS.COM</a></b>	